PREDICTIVE FACTOR OF METASTATIC RENAL CELL CARCINOMA PATIENT IN SARDJITO HOSPITAL PERIOD 2010 - 2015
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: To analyze the association between various prognostic factors and the incidence of renal cell carcinoma (RCC) metastatic. Material & methods: This is a descriptive retrospective study. In this research, the dependent variable is metastatic RCC while the predictor factor as independent variable influencing renal cell carcinoma metastasis. The study population were all patients with renal cell carcinoma that were diagnose in Sardjito Hospital from period 2010 to 2015. Results: In this study there were 34 patients who became the object of research. Consisting of men as many as 20 people (58.8%) while women as many as 14 people (41.2%), while for the age category <51 years as many as 16 people (47.1%) while RCC patients aged > 51 years old 18 People (52.9%). In this study, patients with RCC mostly found in stage 2 were 15 people (44.1%), stage 3 of 6 people (17.6%), stage 4 were 13 people (38.2%). These results are consistent with previous studies which suggest that RCC is found most frequently in stage 2 (Soblin et al, 1997). The p value = < 0.038 indicates that there is a significant correlation between tumor staging and metastatic occurrence in RCC, the result of this study is similar to the previous study which stated that the higher the staging of the tumor the greater the risk of metastasis with p value = 0.001 (Vina et al., 2016). Conclusion: There was a significant association between staging of renal cancer and metastatic events.
##plugins.themes.bootstrap3.article.details##
Renal cell carcinoma, metastatic predictive factor
Novick AC, Burowski RM, Campbell SC. Renal tumors. In: Kavoussi LR, Novick AC, Partin AV, Peters CA (eds) Wein AJ. Campbell-Walls Urology. Philadelphia: WB Saunders; 2007. p. 1565-638.
Globocan 2008. http://globocan.iarc.fr/factsheets/population/factsheet.asp?uno=360. Disitasi December 15; 2014.
Steven D, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: An analysis of the Surveillance, Epidemiology and End Results program data. J Urol. 2002; 167: 57-60.
Vina, Agus R, Chaidir A, Rainy U. Clinical factors predictive of metastases from renal cell carcinomas. Asian Pac J Cancer. 2016; 17(9): 4503-6.
Singam P, Ho C, Goh EH, Mohd A, Tamil AZ, Lee BC, et al. Clinical characteristics of renal cancer in Malaysia: A ten year review. Asian Pacific J Cancer Prev. 2010; 11: 503-6.
Yasunaga, Masaru Shin, Okuyama. Prognostic factor of renal cell carcinoma. Japan; 1998.
Soblin LH, Wittekind C. TNM classification of malignant tumors, 5th Ed. New York: John Wiley; 1997.
Wassim M. Bazzi, Daniel D. Sjoberg. Long-term survival rates after resection for locally advanced kidney cancer. J Urol. June 2015; 193(6): 1911-7.
Kohsuke U, Noriomi M. Recurrence of renal cell carcinoma more than 5 years after nephrectomy. Int J Urol. 2002; 9: 19-23.
Srigley JR, Hutter RV, Gelb AB. Current prognostic factors—renal cell carcinoma: Work Group No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 994-6.
Hannisdal E, Bostad L, Grottum KA, Langmark F. Erythrocyte sedimentation rate as a prognostic factor in renal cell carcinoma. Eur J Surg Oncol. 1999; 15: 333-6.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8): 2530-40.
Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012; 30(27): 3402-7.